for the % of work time missed. PtGA scores were higher than PhGA, in each group and gender.

**Conclusion:** At diagnosis, SpA patients perceive a slightly higher disease burden than assessed by Physicians. For PROs other than BASDAI, AxsSpA reported a worse impact than pSpA. Overall, women showed a higher disease impact than men.


**Disclosure of Interests:** Rosario Foti Speakers bureau: Speaker bureau honoraria from Eli Lilly, Sanofi, MSD, Janssen, AbbVie, Bristol-Myers Squibb, Celgene, Roche, Consultant: Consultant fees and/or speaking engagements from Eli Lilly, Sanofi, MSD, Janssen, AbbVie, BMS, Celgene, Roche, Gabriella Cardinale: None declared., Luisa Costa: None declared., Franco Franceschini: None declared., Francesco Ciccia Speakers bureau: Speaker bureau honoraria from AbbVie, Abiogen, Bristol-Myers Squibb, Celgene, Roche, Consultant: Consultant fees from Eli Lilly, Pfizer, Novartis, Roche, Consultant of: Consultant fees from Novartis, Pfizer, Janssen, Eli Lilly, Roche, Celgene, Consultant/research support from: Consultant/research support from Pfizer, Novartis, Celgene, Janssen, Roche, Antonio Marchesoni: None declared., Giuliana Gugino

**Background:** Ankylosing spondylitis (AS) is an immune-mediated rheumatic disease, it belongs to the spectrum of the axial spondyloarthritis. Several elements are important for the pathogenesis of AS - they include interactions in the context of a specific genetic origin between the intestinal microbiome, innate immunity, lymphoid cells and anatomical structures, which are the entheses of the axial skeleton and peripheral joints. The main mediators of the inflammatory process are TNF-α, IL-17 and IL-17A.

**Objectives:** To study the level of TNF-alpha in the serum of patients with ankylosing spondylitis and to assess its relationship with the indices of disease activity before starting therapy with TNF-alpha blockers and in the dynamics after initiation of treatment.

**Methods:** The present study included 50 patients with ankylosing spondylitis and 50 healthy controls. Similar in age, sex, and BMI. Clinical and non-clinical methods of examination and evaluation were used for proper assessment and follow-up of patients. The disease activity indices that were used were BASDAI and ASDAS. Statistical analysis was performed with the IBM SPSS program. v.24. To prove the relationship between the level of TNF-alpha in the serum of patients and disease activity, a correlation analysis of Spearman Rho was used.

**Results:** The level of TNF-α in patients with AS was highest before treatment initiation with biologics, 89.77 ± 36.89 pg / ml, and was significantly higher than that in healthy controls. At the next visit, the TNF-α level decreased to 2759 ± 23.88 pg / ml, the difference being significant from baseline. 24 months after initiation of treatment with biological therapy average level of TNF-α in patients with AS did not differ reliably from its levels in 6 and 12 month after initiation of treatment, respectively, 22.36 ± 2.38 pg/ml, 19.29 ± 2.01 pg/ml. The level of this cytokine significantly correlates with the activity of the disease, measured by the activity indices BASDAI, ASDAS.

**Conclusion:** The level of the pro-inflammatory cytokine TNF-alpha is significantly higher in patients with ankylosing spondylitis and significantly correlates with the disease activity in them, measured by the respective indices (BASDAI, ASDAS).

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.931

**AB0450**

**IMPACT OF SPONDYLOARTHRITIS ON WORK PRODUCTIVITY: A REAL LIFE STUDY**

M. Ben Majdouba1, S. Boussaid2,1, S. Rekik1, S. Jemmali1, H. Aljani1, H. Sahl1, M. Elieucho1, 1La Rabta hospital, Rheumatology, Tunis, Tunisia

**Background:** Work productivity of patients with spondyloarthritis is frequently affected by their disease.

**Objectives:** We aim to identify disease-related factors associated with poor work productivity in patients with spondyloarthritis.

**Methods:** A cross-sectional study was performed in patients with spondyloarthritis. Data on disease characteristics were collected as well as specific indices: Visual analogue scale (VAS) for fatigue and pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP), Bath Ankylosing Spondylitis Functionnal Index (BASFI) and Bath Ankylosing Spondylitis Metropology Index (BASMI). EuroQol-5D (EQSD) was used to assess health-related quality of life. Work productivity was assessed by the Work Productivity and Activity Impairment scale (WPAI). Factors associated with presenteeism, absenteeism and work productivity loss were evaluated.

**Results:** One hundred patients were enrolled (73 men and 27 women); mean age was 43.68 ± 10.3 years. Fifty nine percent of patients were employed, 26% were off work and 15% were retired of which 8% were in early retirement. Sixty seven percent of patients had ankylosing spondylitis, 17% had rheumatoid arthritis associated with inflammatory bowel disease and 16% had psoriatic rheumatism. The average disease duration was 12.24 ± 8.73 years. Mean age at onset was 33.2 ± 10 years [18-59]. The average diagnostic delay was 2.41 ± 3 years; it was more than five years in 17% of cases. Sacroiliac pain has been noted in 69 patients, lumbar or cervical stiffness in 78 patients and peripheral joint involvement in 18 cases. Thirty one percent of patients had hip joint involvement and 49% had extra-articular manifestations. Fifty percent had inflammatory biological syndrome. 63% were treated with anti-TNFα and 58% needed symptomatic treatment regularly. The mean fatigue and pain VAS was respectively 5.58 ± 2.5 and 5.56 ± 2.9. The mean BASDAI was 4.4 ± 2.4, the mean BASFI was 4.6 ± 2.7 and the average ASDAS-CRP was 2.77 ± 1.18. The mean BASMI was 4.4 ± 2.8. The mean EQSD score was 0.485 ± 0.378. Among employed patients, mean absenteeism, presenteeism and work productivity loss was 21.8 ± 33.1%. 42 ± 32% and 46.5 ± 35.3%, respectively. These work outcomes were correlated to diagnostic delay ≥ 2 years (p<0.03), peripheral joint involvement (p<0.006), level of fatigue and pain VAS ≥ 4 (p<0.001), fatigue and pain BASMI ≥ 4 (p<0.001), BASMI ≥ 4, and low EQSD score (p<0.001): Work productivity loss was in addition correlated to age at onset < 25 years (p<0.03).

**Conclusion:** Active disease, reduced physical function and poorer quality of life are associated with reduced work productivity. Early diagnosis and good disease management especially fatigue and pain can potentially improve work outcomes in patients with spondyloarthritis.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.1079